Optimal and sustainable management of
schizophrenia and bipolar disorder improves
the well-being of patients
04 May 2018
Scientists unveiled genetics behind schizophrenia that may provide new clues on treating the disease
Globally, one in four people will be affected by psychiatric or neurological disorders during their lifetime.1 With an estimated affected population of 450 million people, mental disorders are among the leading causes of ill-health and disability worldwide.1 At the recent Lundbeck Neuroscience Symposium held at Hilton Kota Kinabalu from 3–5 November 2017, three renowned key opinion leaders from the field of psychiatry shared their insights into the optimal management of bipolar disorder and schizophrenia.
Related MIMS Drugs